Costs of treatment in patients with moderate to severe plaque psoriasis: Economic analysis in a randomized controlled comparison of methotrexate and cyclosporine

Archives of Dermatology

Volumn 140, Issue 6, 2004, Pages 685-690

  Opmeer, Brent C ^a   Heydendael, Vera M R ^a   De Borgie, Corianne A J M ^a   Spuls, Phyllis I ^a   Bossuyt, Patrick M M ^a   Bos, Jan D ^a   De Rie, Menno A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OUTPATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SOCIOECONOMICS;

ADMINISTRATION, ORAL; ADULT; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CYCLOSPORINE; DERMATOLOGY; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITAL COSTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; NETHERLANDS; OUTPATIENT CLINICS, HOSPITAL; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2942517673     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.6.685     Document Type: Article

References (20)

1. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol. 1997;137:943-949.
2. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1-125.
3. Riteco JA, Heij LJ, Luijn JC, Wolff I. Richtlijnen voor Farmaco-economisch Onderzoek [Guidelines for Pharmaco-economic Research]. Amstelveen, the Netherlands: College voor Zorgverzekeringen; 1999.
4. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658-665.
5. Fredricksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157:238-244.
6. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care. 1992;30:473-483.
7. Gold MR, Siegel JE, Russel LB. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
8. Oostenbrink JB, Koopmanschap MA, Rutten FF. Handleiding voor Kostenonderzoek: Methoden en Richtlijnprijzen voor Economische Evaluaties in de Gezondheidszorg. Amstelveen, the Netherlands: College voor Zorgverzekeringen; 2000.
9. van Roijen L, Essink-Bot ML, Koopmanschap MA, Bonsel G, Rutten FF. Labor and health status in economic evaluation of health care: the Health and Labor Questionnaire. Int J Technol Assess Health Care. 1996;12:405-415.
10. de Rie MA, de Hoop D, Jonsson L, Bakkers EJ, Sorensen M. Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands. Dermatology. 2001;202:38-43.
11. Enomoto DN, Mekkes JR, de Borgie CA, Bossuyt PM, Bos JD. Behandeling van Patiënten met Chronische Progressieve Sclerodermie met Behulp van Fotoferese [Treatment of Diffuse Systemic Sclerosis With Photopheresis]. Amsterdam, the Netherlands: Academic Medical Center/University of Amsterdam; 1996.
12. Van der Kuy A. Farmacotherapeutisch Kompas 2000/2001 [Pharmacotherapeutic Compass 2000/2001]. Amstelveen, the Netherlands: College voor Zorgverzekeringen; 2000.
13. Huiskes LG. Tarieflijst Instellingen 2001 [Tariff List Institutions 2001]. Utrecht, the Netherlands: College Tarieven Gezondheidszorg, National Health Tariffs Authority; 2000.
14. Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstadter F, Landthaler M, Stolz W. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol. 2001;144:1154-1160.
15. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515-1524.
16. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309-319.
17. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol. 2002;46: 242-250.
18. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41:581-583.
19. van de Kerkhof PC, de Hoop D, De Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200:292-298.
20. Llewellyn-Thomas HA. Investigating patients' preferences for different treatment options. Can J Nurs Res. 1997;29:45-64.